eEF1A2 Protein Expression Correlates with Lymph Node Metastasis and Decreased Survival in Pancreatic Ductal Adenocarcinoma
eEF1A2 Protein Expression Correlates with Lymph Node Metastasis and Decreased Survival in Pancreatic Ductal Adenocarcinoma
复制标题
eEF1A2 蛋白表达与胰腺导管腺癌淋巴结转移和生存率降低相关
DOI：
10.5754/hge12869
复制
发表时间：
2013-06-01
影响因子：
--
通讯作者：
Zhu Qi
中科院分区：
文献类型：
--
作者：
Hu Duanmin;Xu Chao;Zhu Qi
目的：检测真核细胞延伸因子1A2(EEF1A2)在胰腺导管腺癌(PDA)中的表达，并分析其与PDA临床病理的关系。方法：采用免疫组织化学方法检测97例FDA组织中eEF1A2的表达。我们还分析了PDAC细胞中eEF1A2的表达与FDA患者临床病理的关系。结果：正常胰腺组织中不表达eEF1A2。而在PDA中，97例FDA中有76例(77.8%)eEF1A2呈阳性表达。我们发现eEF1A2表达增加与淋巴结转移(p=0.039)和神经侵袭(p=0.043)显著相关。单因素生存分析显示，eEF1A2阳性的FDA患者的中位总生存时间(11.7个月)明显短于eEF1A2阴性的PDAC患者(17.5个月；P
Background/Aims: To examine eukaryotic elongation factor1A2 (eEF1A2) expression in pancreatic ductal adenocarcinoma (PDA) and to analyze its relationship with the clinicopathology of PDA. Methodology: eEF1A2 expression was examined in 97 FDA specimens by immunohistochemistry. We also analyzed the association between eEF1A2 expression in PDAC cells and the clinicopathology of FDA patients. Results: eEF1A2 expression was absent in normal pancreatic tissue. In contrast, in PDA, eEF1A2 showed positive immunoreactivity in 76 of 97 (77.8%) FDA cases. We found significant associations between increased eEF1A2 expression and the presence of nodal metastasis (p=0.039) and perineural invasion (p=0.043). Univariate analysis of survival showed that the median overall survival time of eEF1A2-positive FDA patients (11.7 months) was significantly shorter than that of eEF1A2-negative PDAC patients (17.5 months; p